Teva's Biaxin XL Generic Would Irreparably Harm Abbott, Court Rules
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva is preliminarily enjoined from launching extended-release clarithromycin pending a ruling on the merits of patent infringement claims. A Chicago federal judge preliminarily rules that only one of three Abbott patents at issue is valid. Teva expects to file an expedited appeal to the Federal Circuit.
You may also be interested in...
Abbott Reaches Settlement With Teva On Biaxin XL
Abbott is not releasing the terms of the agreement and said it is pursuing a lawsuit against Andrx.
Abbott Reaches Settlement With Teva On Biaxin XL
Abbott is not releasing the terms of the agreement and said it is pursuing a lawsuit against Andrx.
Biaxin XL Unlikely To Face Generic Competition In Near-Term Following Preliminary Injunctions
Ranbaxy says it will seek to amend its ANDA for a 500 mg dose to carve out labeling language that may be protected by an Abbott patent.